Switch theme
Sign up to access all valuation multiples
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
2017
106
LTM Revenue n/a
LTM EBITDA -$143M
$11.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biomea Fusion has a last 12-month revenue of n/a and a last 12-month EBITDA of -$143M.
In the most recent fiscal year, Biomea Fusion achieved revenue of n/a and an EBITDA of -$142M.
Biomea Fusion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biomea Fusion valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$125M | -$142M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$81.8M | -$117M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Biomea Fusion's stock price is $2.
Biomea Fusion has current market cap of $60.9M, and EV of $11.4M.
See Biomea Fusion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.4M | $60.9M | XXX | XXX | XXX | XXX | $-3.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Biomea Fusion has market cap of $60.9M and EV of $11.4M.
Biomea Fusion's trades at n/a LTM EV/Revenue multiple, and -0.1x LTM EBITDA.
Analysts estimate Biomea Fusion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Biomea Fusion and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $11.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.1x | XXX | XXX | XXX |
| P/E | -0.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBiomea Fusion's NTM/LTM revenue growth is Infinity%
Biomea Fusion's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.4M for the same period.
Over next 12 months, Biomea Fusion's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Biomea Fusion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Biomea Fusion and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biomea Fusion acquired XXX companies to date.
Last acquisition by Biomea Fusion was XXXXXXXX, XXXXX XXXXX XXXXXX . Biomea Fusion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Biomea Fusion founded? | Biomea Fusion was founded in 2017. |
| Where is Biomea Fusion headquartered? | Biomea Fusion is headquartered in United States of America. |
| How many employees does Biomea Fusion have? | As of today, Biomea Fusion has 106 employees. |
| Who is the CEO of Biomea Fusion? | Biomea Fusion's CEO is Dr. Michael J. M. Hitchcock, PhD. |
| Is Biomea Fusion publicy listed? | Yes, Biomea Fusion is a public company listed on NAS. |
| What is the stock symbol of Biomea Fusion? | Biomea Fusion trades under BMEA ticker. |
| When did Biomea Fusion go public? | Biomea Fusion went public in 2021. |
| Who are competitors of Biomea Fusion? | Similar companies to Biomea Fusion include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Biomea Fusion? | Biomea Fusion's current market cap is $60.9M |
| What is the current EBITDA of Biomea Fusion? | Biomea Fusion's last 12-month EBITDA is -$143M. |
| What is the current EV/EBITDA multiple of Biomea Fusion? | Current EBITDA multiple of Biomea Fusion is -0.1x. |
| Is Biomea Fusion profitable? | Yes, Biomea Fusion is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
